Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial [0.03%]
长效广谱中和抗体3BNC117-LS和10-1074-LS输注后恢复体内水平及分析性治疗中断试验（里奥研究）：一项双盲、随机、安慰剂对照试验
Ming J Lee,Louise-Rae Cherrill,Panagiota Zacharopoulou et al.
Ming J Lee et al.
Background: HIV-specific broadly neutralising antibodies (bNAbs) can maintain viral control after interrupting antiretroviral therapy (ART). We investigated the duration and efficacy of Fc-engineered long-acting bNAbs (LS...
Trends in AIDS-defining illnesses among people living with HIV in clinical care in Europe: results from the EuroSIDA multicentre cohort study (2003-24) [0.03%]
欧洲临床护理人群中艾滋病定义疾病的流行趋势：来自EuroSIDA多中心队列研究（2003-2024年）的结果
Wendy P Bannister,Joanne Reekie,Lars Peters et al.
Wendy P Bannister et al.
Background: Despite substantial declines in AIDS-defining illnesses following implementation of treat-all policies across Europe, these conditions remain a substantial cause of morbidity and mortality among people with HI...
Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trial [0.03%]
HIV感染者的4天/周服药间隔的二联维持治疗：一项开放标签、多中心非劣效性随机对照试验（ANRS-177 DUETTO）
Roland Landman,Lambert Assoumou,Sidonie Lambert-Niclot et al.
Roland Landman et al.
Background: Previous trials have validated the strategy of short-cycle three-drug (triple) antiretroviral therapy for HIV treatment. The main objective of ANRS-177 DUETTO was to assess whether a two-drug (dual) regimen ta...
Are screening periods in ART-naive trials justified in the era of rapid ART? [0.03%]
在快速抗逆转录病毒治疗时代，未接受过抗逆转录病毒治疗的试验中的筛查期是否合理？
William R Short,Serena Koenig,Pablo Tebas et al.
William R Short et al.
Talha Burki
Talha Burki
Cahal McQuillan
Cahal McQuillan
Roger Pebody
Roger Pebody
Irma Kirtadze,Lynn M Madden,David Otiashvili et al.
Irma Kirtadze et al.
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial [0.03%]
PGDM1400LS、VRC07-523LS 和 PGT121.414.LS 静脉注射或皮下注射的 I 期随机试验：安全性和药代动力学以及中和活性（HVTN 140/HPTN 101 第 B 部分）
Sharana Mahomed,Carmen A Paez,Yunda Huang et al.
Sharana Mahomed et al.
Background: Passive immunisation with a combination of broadly neutralising monoclonal antibodies (mAbs) presents a potential HIV-1 prevention modality. This study (HVTN 140/HPTN 101) sought to evaluate PGDM1400LS (target...
Global mental health disparities among transgender women and transfeminine people living with HIV: a systematic review and meta-analysis of 63 studies [0.03%]
系统评价与meta分析：六十三项研究中关于感染HIV的跨性别女性和男变女跨性别者的全球精神健康差异
David R A Coelho,Maria L R Defante,Rômulo da Silva Sanglard et al.
David R A Coelho et al.
Background: Transgender women and transfeminine people face a disproportionate burden of mental health conditions driven by stigma, discrimination, and structural inequities, with additional psychosocial challenges relate...